, Volume 16, Issue 4, pp 229–239 | Cite as

Gene Therapy in Infants with Severe Combined Immunodeficiency

  • Makoto Otsu
  • Fabio Candotti
Gene Therapy


Severe combined immunodeficiencies (SCID) are rare disorders that represent paediatric medical emergencies, as the outcome for affected patients can easily be fatal unless proper treatment is performed. The only curative treatment for SCID is reconstitution of the patient’s immunity. For more than 30 years, allogeneic bone marrow transplantation (BMT) has been extremely successful for SCID. However, BMT often results in only incomplete restoration of B cell function in treated patients, especially when haploidentical donors are used. In addition, BMT can be associated with severe complications such as graft-versus-host disease (GVHD). Alternative forms of therapy for SCID are therefore desirable. Genetic correction of peripheral T lymphocytes and/or haematopoietic stem cells (HSCs) by retrovirally mediated gene transfer has been attempted for patients with SCID due to adenosine deaminase deficiency, the first genetic disease targeted in clinical gene therapy trials with very limited success, overall. After these pioneer trials, recent progress has led to significant improvement of gene transfer techniques and better understanding of HSC biology which has culminated in the recent success of a gene therapy trial for patients affected with X-linked SCID (X-SCID). In this trial, patients with X-SCID received autologous bone marrow stem/progenitor cells which had been retrovirally transduced with a therapeutic gene. Based on the current follow-up, the overall efficacy of this gene therapy procedure is to be considered similar to or even better than that achievable by allogeneic BMT, because patients were not exposed to the risks of GVHD. Although these exciting results have clearly demonstrated that gene therapy is a feasible therapeutic option for X-SCID, they have also raised important questions regarding the long-term outcome of this experimental procedure and the possibility of translating this success into applications for other forms of SCID.


Gene Therapy Bone Marrow Transplantation Allogeneic Bone Marrow Transplantation Severe Combine Immunodeficiency Gene Therapy Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343(18): 1313–24PubMedCrossRefGoogle Scholar
  2. 2.
    Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130(3): 378–87PubMedCrossRefGoogle Scholar
  3. 3.
    Fischer A, Cavazzana-Calvo M, De Saint Basile G, et al. Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol 1997; 15: 93–124PubMedCrossRefGoogle Scholar
  4. 4.
    Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J Pediatr 1999; 134(6): 740–8PubMedCrossRefGoogle Scholar
  5. 5.
    Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340(7): 508–16PubMedCrossRefGoogle Scholar
  6. 6.
    van Leeuwen JE, van Tol MJ, Joosten AM, et al. Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. Blood 1994; 84(11): 3936–47PubMedGoogle Scholar
  7. 7.
    Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91(10): 3646–53PubMedGoogle Scholar
  8. 8.
    Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood 1998; 92(10): 3949–59PubMedGoogle Scholar
  9. 9.
    Hershfield MS. Immunodeficiency caused by adenosine deaminase deficiency. Immunol All Clin N Am 2000; 20(1): 161–75CrossRefGoogle Scholar
  10. 10.
    Hirschhorn R, Yang DR, Puck JM, et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet 1996; 13(3): 290–5PubMedCrossRefGoogle Scholar
  11. 11.
    Bousso P, Wahn V, Douagi I, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci U S A 2000; 97(1): 274–8PubMedCrossRefGoogle Scholar
  12. 12.
    Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270(5235): 470–5PubMedCrossRefGoogle Scholar
  13. 13.
    Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270(5235): 475–80PubMedCrossRefGoogle Scholar
  14. 14.
    Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995; 1(10): 1017–23PubMedCrossRefGoogle Scholar
  15. 15.
    Hoogerbrugge PM, vanBeusechem VW, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996; 3(2): 179–83PubMedGoogle Scholar
  16. 16.
    Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998; 91(1): 30–6PubMedGoogle Scholar
  17. 17.
    Crooks GM, Kohn DB. Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells. Blood 1993; 82(11): 3290–7PubMedGoogle Scholar
  18. 18.
    Orlic D, Girard LJ, Jordan CT, et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A 1996; 93(20): 11097–102PubMedCrossRefGoogle Scholar
  19. 19.
    Miller AD, Garcia JV, von Suhr N, et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65(5): 2220–4PubMedGoogle Scholar
  20. 20.
    Sabatino DE, Do BQ, Pyle LC, et al. Amphotropic or gibbon ape leukemia virus retrovirus binding and transduction correlates with the level of receptor mRNA in human hematopoietic cell lines. Blood Cells Mol Dis 1997; 23(3): 422–33PubMedCrossRefGoogle Scholar
  21. 21.
    Kiem HP, Heyward S, Winkler A, et al. Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 1997; 90(11): 4638–45PubMedGoogle Scholar
  22. 22.
    Cosset FL, Takeuchi Y, Battini JL, et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69(12): 7430–6PubMedGoogle Scholar
  23. 23.
    Yang Y, Vanin EF, Whitt MA, et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther 1995; 6(9): 1203–13PubMedCrossRefGoogle Scholar
  24. 24.
    Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 1996; 93(21): 11400–6PubMedCrossRefGoogle Scholar
  25. 25.
    Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 2000; 11(9): 1259–67PubMedCrossRefGoogle Scholar
  26. 26.
    Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263–7PubMedCrossRefGoogle Scholar
  27. 27.
    Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2(5): 308–16PubMedCrossRefGoogle Scholar
  28. 28.
    Akkina RK, Walton RM, Chen ML, et al. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70(4): 2581–5PubMedGoogle Scholar
  29. 29.
    Uchida N, Sutton RE, Friera AM, et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A 1998; 95(20): 11939–44PubMedCrossRefGoogle Scholar
  30. 30.
    Sutton RE, Wu HT, Rigg R, et al. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol 1998; 72(7): 5781–8PubMedGoogle Scholar
  31. 31.
    Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283(5402): 682–6PubMedCrossRefGoogle Scholar
  32. 32.
    An DS, Wersto RP, Agricola BA, et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34 (+) cells. J Virol 2000; 74(3): 1286–95PubMedCrossRefGoogle Scholar
  33. 33.
    Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+) CD38(−) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 1999; 96(6): 2988–93PubMedCrossRefGoogle Scholar
  34. 34.
    Guenechea G, Gan OI, Inamitsu T, et al. Transduction of human CD34+ CD38− bone marrow and cord blood-derived SCID-repopulating cells with thirdgeneration lentiviral vectors. Mol Ther 2000; 1(6): 566–73PubMedCrossRefGoogle Scholar
  35. 35.
    Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72(11): 8463–71PubMedGoogle Scholar
  36. 36.
    Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72(12): 9873–80PubMedGoogle Scholar
  37. 37.
    Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998; 72(10): 8150–7PubMedGoogle Scholar
  38. 38.
    Dao MA, Hannum CH, Kohn DB, et al. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immunedeficient mice after ex vivo retroviral-mediated transduction. Blood 1997; 89(2): 446–56PubMedGoogle Scholar
  39. 39.
    Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10(8): 4239–42PubMedGoogle Scholar
  40. 40.
    Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89(8): 2644–53PubMedGoogle Scholar
  41. 41.
    Kiem HP, Andrews RG, Morris J, et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 1998; 92(6): 1878–86PubMedGoogle Scholar
  42. 42.
    Hennemann B, Conneally E, Pawliuk R, et al. Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 1999; 27(5): 817–25PubMedCrossRefGoogle Scholar
  43. 43.
    Moritz T, Patel VP, Williams DA. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest 1994; 93(4): 1451–7PubMedCrossRefGoogle Scholar
  44. 44.
    Hanenberg H, Xiao XL, Dilloo D, et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2(8): 876–82PubMedCrossRefGoogle Scholar
  45. 45.
    Moritz T, Dutt P, Xiao X, et al. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 1996; 88(3): 855–62PubMedGoogle Scholar
  46. 46.
    Hanenberg H, Hashino K, Konishi H, et al. Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 1997; 8(18): 2193–206PubMedCrossRefGoogle Scholar
  47. 47.
    Dao MA, Hashino K, Kato I, et al. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 1998; 92(12): 4612–21PubMedGoogle Scholar
  48. 48.
    Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94(22): 12133–8PubMedCrossRefGoogle Scholar
  49. 49.
    Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–72PubMedCrossRefGoogle Scholar
  50. 50.
    Daddona PE, Kelley WN. Human adenosine deaminase. Purification and subunit structure. J Biol Chem 1977; 252(1): 110–5PubMedGoogle Scholar
  51. 51.
    Schrader WP, Stacy AR. Purification and subunit structure of adenosine deaminase from human kidney. J Biol Chem 1977; 252(18): 6409–15PubMedGoogle Scholar
  52. 52.
    Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; II(7786): 1067–9CrossRefGoogle Scholar
  53. 53.
    Hirschhorn R. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr Res 1993; 33 Suppl. 1: S35–41CrossRefGoogle Scholar
  54. 54.
    Markert ML. Molecular basis of adenosine deaminase deficiency. Immunodeficiency 1994; 5(2): 141–57PubMedGoogle Scholar
  55. 55.
    Hirschhorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. In: Ochs HD, Edvard Smith CI, Puck JM, editors. Primary immunodeficiency diseases. New York: Oxford University Press, 1999: 121–39Google Scholar
  56. 56.
    Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993; 123(4): 564–72PubMedCrossRefGoogle Scholar
  57. 57.
    Migchielsen AA, Breuer ML, van Roon MA, et al. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 1995; 10(3): 279–87PubMedCrossRefGoogle Scholar
  58. 58.
    Wakamiya M, Blackburn MR, Jurecic R, et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci U S A 1995; 92(9): 3673–7PubMedCrossRefGoogle Scholar
  59. 59.
    Blackburn MR, Aldrich M, Volmer JB, et al. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice: differential impact on pulmonary and immunologic abnormalities. J Biol Chem 2000; 275(41): 32114–21PubMedCrossRefGoogle Scholar
  60. 60.
    Thompson LF, Van de Wiele CJ, Laurent AB, et al. Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures. J Clin Invest 2000; 106(9): 1149–57PubMedCrossRefGoogle Scholar
  61. 61.
    Aiuti A, Slavin S, Aker M, et al. Correction of ASA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410–3PubMedCrossRefGoogle Scholar
  62. 62.
    Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73(1): 147–57PubMedCrossRefGoogle Scholar
  63. 63.
    Puck JM, Deschenes SM, Porter JC, al The interleukin-2 receptor gamma chain maps to Xql3.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993; 2(8): 1099–104PubMedCrossRefGoogle Scholar
  64. 64.
    Leonard WJ, Shores EW, Love PE. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol Rev 1995; 148: 97–114PubMedCrossRefGoogle Scholar
  65. 65.
    Sugamura K, Asao H, Kondo M, et al. The common gamma-chain for multiple cytokine receptors. Adv Immunol 1995; 59: 225–77PubMedCrossRefGoogle Scholar
  66. 66.
    DiSanto JP, Kuhn R, Muller W. Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting. Immunol Rev 1995; 148:19–34PubMedCrossRefGoogle Scholar
  67. 67.
    Buckley RH. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res 2001; 22(2-3): 237–51CrossRefGoogle Scholar
  68. 68.
    Candotti F, Johnston JA, Puck JM, et al. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 1996; 87(8): 3097–102PubMedGoogle Scholar
  69. 69.
    Taylor N, Uribe L, Smith S, et al. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene. Blood 1996; 87(8): 3103–7PubMedGoogle Scholar
  70. 70.
    Hacein-Bey H, Cavazzana-Calvo M, Le Deist F, et al. Gamma-c gene transfer into SCID X1 patients’ B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 1996; 87(8): 3108–16PubMedGoogle Scholar
  71. 71.
    Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency XI bone marrow cells. Blood 1996; 88(10): 3901–9PubMedGoogle Scholar
  72. 72.
    Hacein-Bey S, Basile GD, Lemerle J, et al. Gamma c gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gamma c (−) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 1998; 92(11): 4090–7PubMedGoogle Scholar
  73. 73.
    DiSanto JP, Muller W, Guy-Grand D, et al. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A 1995; 92(2): 377–81PubMedCrossRefGoogle Scholar
  74. 74.
    Cao X, Shores EW, Hu-Li J, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995; 2(3): 223–38PubMedCrossRefGoogle Scholar
  75. 75.
    Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996; 87(3): 956–67PubMedGoogle Scholar
  76. 76.
    Jacobs H, Krimpenfort P, Haks M, et al. PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in rag-but not CD3gamma-deficient mice. J Exp Med 1999; 190(8): 1059–68PubMedCrossRefGoogle Scholar
  77. 77.
    Lo M, Bloom ML, Imada K, et al. Restoration of lymphoid populations in a murine model of x-linked severe combined immunodeficiency by a gene-therapy approach. Blood 1999; 94: 3027–36PubMedGoogle Scholar
  78. 78.
    Otsu M, Anderson S, Bodine D, et al. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 2000; 1(2): 145–53PubMedCrossRefGoogle Scholar
  79. 79.
    Soudais C, Shiho T, Sharara LI, et al. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 2000; 95(10): 3071–7PubMedGoogle Scholar
  80. 80.
    Hacien-Bey-Abina S, LeDeist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185–93CrossRefGoogle Scholar
  81. 81.
    Macchi P, Villa A, Gillani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377(6544): 65–8PubMedCrossRefGoogle Scholar
  82. 82.
    Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270(5237): 797–800PubMedCrossRefGoogle Scholar
  83. 83.
    Thomis DC, Gurniak CB, Tivol E, et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270(5237): 794–7PubMedCrossRefGoogle Scholar
  84. 84.
    Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270(5237): 800–2PubMedCrossRefGoogle Scholar
  85. 85.
    Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995; 3(6): 771–82PubMedCrossRefGoogle Scholar
  86. 86.
    Candotti F, Oakes SA, Johnston JA, et al. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med 1996; 183(6): 2687–92PubMedCrossRefGoogle Scholar
  87. 87.
    Oakes SA, Candotti F, Johnston JA, et al. Signaling via IL-2 and IL-4 in JAK3-de-ficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996; 5(6): 605–15PubMedCrossRefGoogle Scholar
  88. 88.
    Bunting KD, Sangster MY, Ihle JN, et al. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998; 4(1): 58–64PubMedCrossRefGoogle Scholar
  89. 89.
    Bunting KD, Lu T, Kelly PF, et al. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum Gene Ther 2000; 11(17): 2353–64PubMedCrossRefGoogle Scholar
  90. 90.
    Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293–322PubMedCrossRefGoogle Scholar
  91. 91.
    Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T(−)B (+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol 2000; 12(4): 468–73PubMedCrossRefGoogle Scholar
  92. 92.
    Puel A, Ziegler SF, Buckley RH, et al. Defective IL7R expression in T(−) B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20(4): 394–7PubMedCrossRefGoogle Scholar
  93. 93.
    Roifman CM, Zhang J, Chitayat D, et al. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000; 96(8): 2803–7PubMedGoogle Scholar
  94. 94.
    vonFreeden-Jeffry U, Vieira P, Lucian LA, et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181(4): 1519–26CrossRefGoogle Scholar
  95. 95.
    Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180(5): 1955–60PubMedCrossRefGoogle Scholar
  96. 96.
    Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell-negative SCID. Science 1996; 274(5284): 97–9PubMedCrossRefGoogle Scholar
  97. 97.
    Notarangelo LD, Villa A, Schwarz K. RAG and RAG defects. Curr Opin Immunol 1999; 11(4): 435–42PubMedCrossRefGoogle Scholar
  98. 98.
    Willerford DM, Swat W, Alt FW. Developmental regulation of V (D)J recombination and lymphocyte differentiation. Curr Opin Genet Dev 1996; 6(5): 603–9PubMedCrossRefGoogle Scholar
  99. 99.
    Hikida M, Mori M, Takai T, et al. Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells. Science 1996; 274(5295): 2092–4PubMedCrossRefGoogle Scholar
  100. 100.
    Han S, Zheng B, Schatz DG, et al. Neoteny in lymphocytes: Ragl and Rag2 expression in germinal center B cells. Science 1996; 274(5295): 2094–7PubMedCrossRefGoogle Scholar
  101. 101.
    Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V (D)J rearrangement. Cell 1992; 68(5): 855–67PubMedCrossRefGoogle Scholar
  102. 102.
    Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68(5): 869–77PubMedCrossRefGoogle Scholar
  103. 103.
    Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V (D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001; 105(2): 177–86PubMedCrossRefGoogle Scholar
  104. 104.
    Cale CM, Klein NJ, Novelli V, et al. Severe combined immunodeficiency with abnormalities in expression of the common leucocyte antigen, CD45. Arch Dis Child 1997; 76(2): 163–4PubMedCrossRefGoogle Scholar
  105. 105.
    Kung C, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 2000; 6(3): 343–5PubMedCrossRefGoogle Scholar
  106. 106.
    Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994; 264(5165): 1596–9PubMedCrossRefGoogle Scholar
  107. 107.
    Arpaia E, Shahar M, Dadi H, et al. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 1994; 76(5): 947–58PubMedCrossRefGoogle Scholar
  108. 108.
    Taylor N, Bacon KB, Smith S, et al. Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene. J Exp Med 1996; 184(5): 2031–6PubMedCrossRefGoogle Scholar
  109. 109.
    Steinberg M, Swainson L, Schwarz K, et al. Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy. Gene Ther 2000; 7(16): 1392–400PubMedCrossRefGoogle Scholar
  110. 110.
    Puck JM, Pepper AE, Henthorn PS, et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 1997; 89(6): 1968–77PubMedGoogle Scholar
  111. 111.
    Kawahara A, Minami Y, Taniguchi T. Evidence for a critical role for the cytoplasmic region of the interleukin 2 (IL-2) receptor gamma chain in IL-2, IL-4, and IL-7 signalling. Mol Cell Biol 1994; 14(8): 5433–40PubMedGoogle Scholar
  112. 112.
    Otsu M, Sugamura K, Candotti F. Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice. Blood 2001; 97(6): 1618–24PubMedCrossRefGoogle Scholar
  113. 113.
    Otsu M, Sugamura K, Candotti F. In vivo competitive studies between normal and common gamma chain-defective bone marrow cells: implications for gene therapy. Hum Gene Ther 2000; 11(14): 2051–6PubMedCrossRefGoogle Scholar
  114. 114.
    Conley ME, Lavoie A, Briggs C, et al. Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency. Proc Natl Acad Sci U S A 1988; 85(9): 3090–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Genetics and Molecular Biology BranchNational Human Genome Research Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations